{
    "clinical_study": {
        "@rank": "87533", 
        "arm_group": [
            {
                "arm_group_label": "BioChaperone insulin lispro 0.2U/Kg", 
                "arm_group_type": "Experimental", 
                "description": "BioChaperone insulin lispro 0.2U/Kg"
            }, 
            {
                "arm_group_label": "BioChaperone insulin lispro 0.1U/Kg", 
                "arm_group_type": "Experimental", 
                "description": "BioChaperone insulin lispro 0.1U/Kg"
            }, 
            {
                "arm_group_label": "BioChaperone insulin lispro 0.4U/Kg", 
                "arm_group_type": "Experimental", 
                "description": "BioChaperone insulin lispro 0.4U/Kg"
            }, 
            {
                "arm_group_label": "Humalog\u00ae 0.2U/Kg", 
                "arm_group_type": "Active Comparator", 
                "description": "Humalog\u00ae 0.2U/Kg"
            }
        ], 
        "brief_summary": {
            "textblock": "The addition of BioChaperone to insulin lispro may accelerate the onset and shorten the\n      duration of action of insulin lispro due to facilitation of the absorption of the insulin\n      after subcutaneous injection.\n\n      The aim of the trial is to investigate the dose-response and the dose-exposure relationships\n      of BioChaperone insulin lispro under 3 doses, to compare the pharmacokinetics and\n      glucodynamic action of BioChaperone insulin lispro at 0.2U/Kg with Humalog\u00ae at 0.2 U/Kg and\n      to assess safety and tolerability of BioChaperone insulin lispro and Humalog\u00ae.\n\n      This is a double-blinded, randomised, four-period crossover phase 2 trial using automated\n      12-hour euglycemic clamps in subject with type 1 diabetes mellitus.\n\n      Each subject will be randomly allocated to a sequence of 4 treatments, i.e. with one of\n      three single doses of BioChaperone insulin lispro (0.1, 0.2 and 0.4 U/Kg) or one single dose\n      of Humalog\u00ae (0.2 U/Kg) on 4 separate dosing visits."
        }, 
        "brief_title": "A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus Type 1", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes mellitus for at least 12 months\n\n          -  Treated with multiple daily insulin injections of insulin pump for at least 12 months\n\n          -  Body Mass Index (BMI): 18.5-28.0 Kg.m\u00b2\n\n        Exclusion Criteria:\n\n          -  Type 2 diabetes mellitus\n\n          -  Receipt of any investigational product within 3 months prior first dosing\n\n          -  Clinically significant abnormalities as judged by the investigator\n\n          -  Any systemic treatment with drugs known to interfere with glucose metabolism\n\n          -  History of alcoholism or drug/chemical abuse as per investigator's judgement\n\n          -  Use of tobacco or nicotine-contained product within 1 year prior to screening\n\n          -  Blood or plasma donation in the past month or more than 500ml within 3 months prior\n             to screening"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146651", 
            "org_study_id": "BC3-CT008"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BioChaperone insulin lispro 0.2U/Kg", 
                    "BioChaperone insulin lispro 0.1U/Kg", 
                    "BioChaperone insulin lispro 0.4U/Kg", 
                    "Humalog\u00ae 0.2U/Kg"
                ], 
                "description": "Single dose of 0.2U/Kg body weight injected subcutaneously", 
                "intervention_name": "BioChaperone insulin lispro 0.2U/Kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "BioChaperone insulin lispro 0.2U/Kg", 
                    "BioChaperone insulin lispro 0.1U/Kg", 
                    "BioChaperone insulin lispro 0.4U/Kg", 
                    "Humalog\u00ae 0.2U/Kg"
                ], 
                "description": "Single dose of 0.1U/Kg body weight injected subcutaneously", 
                "intervention_name": "BioChaperone insulin lispro 0.1U/Kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "BioChaperone insulin lispro 0.2U/Kg", 
                    "BioChaperone insulin lispro 0.1U/Kg", 
                    "BioChaperone insulin lispro 0.4U/Kg", 
                    "Humalog\u00ae 0.2U/Kg"
                ], 
                "description": "Single dose of 0.4U/Kg body weight injected subcutaneously", 
                "intervention_name": "BioChaperone insulin lispro 0.4U/Kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "BioChaperone insulin lispro 0.2U/Kg", 
                    "BioChaperone insulin lispro 0.1U/Kg", 
                    "BioChaperone insulin lispro 0.4U/Kg", 
                    "Humalog\u00ae 0.2U/Kg"
                ], 
                "description": "Single dose of 0.2U/Kg body weight injected subcutaneously", 
                "intervention_name": "Humalog\u00ae", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin LISPRO", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }, 
                "name": "Profil Institut f\u00fcr stoffwechselforschung GmbH"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes", 
        "overall_contact": {
            "last_name": "Grit Andersen, MD", 
            "phone": "+49 2131 4018-0"
        }, 
        "overall_official": {
            "affiliation": "Profil Institut f\u00fcr Stoffwechselfforschung GmbH", 
            "last_name": "Grit Andersen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the Glucose Infusion Rate time curve from 0 hours until the end of the clamp", 
                "measure": "Glucodynamic endpoint: Area Under the Curve GIR(0-last)", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "description": "Maximum Glucose Infusion Rate", 
                "measure": "Glucodynamic endpoint: GIRMax", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "description": "Area under the insulin lispro serum concentration - time curve over the clamp procedure.", 
                "measure": "Pharmacokinetic endpoint: AUC Lisp(0-last)", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "description": "Maximum observed serum insulin lispro concentration", 
                "measure": "Pharmacokinetic endpoint: Cmax(Lisp)", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146651"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time to maximum observed serum insulin lispro concentration", 
                "measure": "Pharmacokinetics: Tmax(lisp)", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "description": "Time to maximum Glucose Infusion Rate", 
                "measure": "Glucodynamic: TGIRmax", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "description": "Time from t=0 until blood glucose concentration has decreased by 5mg.dL (0.3mmol.L) from baseline.", 
                "measure": "Tonset of action", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "measure": "Safety and Tolerability: adverse events, local tolerability, vital signs variations, ECG, laboratory safety parameters.", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Adocia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Adocia", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}